<DOC>
	<DOCNO>NCT00696592</DOCNO>
	<brief_summary>This phase II study design evaluate safety , tolerability , efficacy bevacizumab treatment conjunction PDT low fluence rate compare bevacizumab alone combine PDT standard fluence rate , patient type choroidal neovascularization secondary AMD . Hypothesis : bevacizumab combination PDT ( low standard fluence rate ) ) delay time retreatment , ii ) reduce average number treatment require compare bevacizumab alone iii ) low PDT fluence rate improve long-term safety profile .</brief_summary>
	<brief_title>Photodynamic Therapy Combined With Bevacizumab v Bevacizumab Alone Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>All lesion subtype CNV secondary agerelated macular . subfoveal CNV . patient fail respond Photodynamic therapy . patient eligible PDT ( Greatest linear dimension lesion &gt; /= 5400 um , CNV hemorrhage &gt; /= 50 % entire lesion , minimally classic occult CNV great linear dimension lesion &gt; /= 4600 um. ) . Patients affect Pigment Epithelium Detachment CNV . Patients affect Retinal Angiomatous Proliferation . Willingness ability participate provide write informed consent . Individuals choroidal neovascularization cause AMD ( Myopia , Angioid Streaks ) . Any intraocular surgery within 2 month study eye . Prior retinal vitreous surgery include posterior segment vitrectomy scleral buckling study eye . Any significant ocular disease compromise could compromise vision study eye . Prior stroke , myocardial infarction , endstage malignancy . Active hepatitis clinically significant liver disease , renal failure . Any patient recent history new onset cardiac disease thromboembolic CNS event past . Patients experimental therapy study receive experimental therapy within last 12 week . Patients poor medical risk systemic disease active uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Photodynamic Therapy</keyword>
</DOC>